Thiogenesis Therapeutics, and Corp. (TSXV: TTI) ("Thiogenesis" or the "Company"), a clinical-stage biotechnology company developing disulfides that drive the production of critically important ...
The European Medicines Agency (EMA) said on Monday it would no longer post on X and would use rival Bluesky instead, becoming ...
The European Medicines Agency (EMA) has decided to stop using the social media platform X due to content concerns and will instead use Bluesky. This move aligns with other organizations stepping back ...
This European review of the prefilled syringe follows GSK's receipt of approval from the US Food & Drug Administration on January 8. GSK is also investigating submission of the new presentation to ...
LONDON - GlaxoSmithKline PLC (LSE/NYSE: NYSE:GSK) announced today that the European Medicines Agency (EMA) has begun ...
As users continue to leave X (formerly Twitter) en masse, many in favor of the newer Bluesky platform, the European Medicines ...
An investigational higher dose of spinal muscular atrophy drug nusinersen gains attention as the FDA and European Medicines Agency (EMA) considerate it as an alternative than the current lower ...
We are pleased to announce that our applications for the higher dose regimen of nusinersen are now under review in the US and Europe,” said Stephanie Fradette, Pharm.D., Head of the Neuromuscular ...
Biogen said the U.S. Food and Drug Administration has accepted its supplemental new-drug application, while the European Medicines Agency has validated its application, which confirms that the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback